There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Avita Medical (RCEL – Research Report) and Better Therapeutics, Inc. (BTTX – Research Report) with bullish sentiments.
Avita Medical (RCEL)
In a report released yesterday, Ryan Zimmerman from BTIG reiterated a Buy rating on Avita Medical, with a price target of $16.00. The company’s shares closed last Thursday at $7.89.
According to TipRanks.com, Zimmerman is a 4-star analyst with an average return of
Currently, the analyst consensus on Avita Medical is a Moderate Buy with an average price target of $16.00.
See today’s best-performing stocks on TipRanks >>
Better Therapeutics, Inc. (BTTX)
In a report released yesterday, Keay Nakae from Chardan Capital maintained a Buy rating on Better Therapeutics, Inc., with a price target of $17.00. The company’s shares closed last Thursday at $1.79, close to its 52-week low of $0.91.
According to TipRanks.com, Nakae is a 4-star analyst with an average return of
Better Therapeutics, Inc. has an analyst consensus of Moderate Buy, with a price target consensus of $15.00, representing a 702.1% upside. In a report issued on July 29, LifeSci Capital also maintained a Buy rating on the stock with a $15.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on RCEL:
- Stifel Nicolaus Sticks to Its Hold Rating for Poshmark (POSH)
- Deutsche Bank Reaffirms Their Buy Rating on Six Flags (SIX)
- Rosenblatt Securities Remains a Buy on PDF Solutions (PDFS)
- Synopsys (SNPS): New Buy Recommendation for This Technology Giant
- SmartCentres Real Estate Investment Trust Releases Second Quarter Results for 2022
